<?xml version="1.0" encoding="UTF-8"?>
<p>At more early stages, the viral RNA polymerase inhibitor favipiravir in combination is also on a Phase II clinical trial for novel coronavirus-associated pneumonia (Chinese Clinical Trial Registry Identifier: ChiCTR2000029544) [
 <xref rid="B10" ref-type="bibr">10</xref>]. Finally, preclinical studies of ribavirin (ribonucleic analog) has shown 
 <italic>in vitro</italic> activity against SARS-CoV-2 [
 <xref rid="B9" ref-type="bibr">9</xref>].
</p>
